Early Supportive Care Reduces Symptom Burden in Phase I Cancer Trial Patients
This randomized controlled trial enrolled 186 patients participating in Phase I clinical trials for cancer. Patients were randomized to an Early Supportive Care (ESC) program, which included multidisciplinary case discussions and referrals to psycho-oncology, social work, and palliative care, or to Standard Care (SC). The primary outcome was symptom burden assessed by the Edmonton Symptom Assessment System (ESAS). Secondary outcomes included psychosocial needs (ENP-E) and sociofamilial needs.
At three monthly follow-ups, the ESC group showed significantly lower symptom burden scores compared to SC (β = -14.44; 95% CI -18.13 to -10.75). Psychosocial needs were also significantly lower in the ESC group (β = -3.38; 95% CI -4.52 to -2.24). Improvements in sociofamilial needs were limited to distance-related and guidance-related items, though effect sizes were not reported.
Safety data, including adverse events and discontinuations, were not reported. The study did not report funding sources or conflicts of interest. Limitations were not explicitly stated, but the single-center design and lack of blinding may affect generalizability.
For clinicians, these findings support early integration of supportive care to improve symptom control and psychosocial well-being in patients enrolled in early-phase cancer trials. However, further research is needed to confirm these results and assess long-term outcomes.